Covered recipient · General Payments record
SARAH E BURCHETT
Allopathic & Osteopathic Physicians Plastic Surgery
General Payments · PY2022–2024
$818.82
- Reported across 37 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $396.28 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $275.91 | 15 |
| Galderma Laboratories, L.P. | $102.34 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.03 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.10 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391337 | CMS |
| ABBVIE INC. | $10.03 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391339 | CMS |
| ABBVIE INC. | $10.03 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391341 | CMS |
| ABBVIE INC. | $11.30 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391343 | CMS |
| ABBVIE INC. | $79.17 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391345 | CMS |
| ABBVIE INC. | $6.51 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391347 | CMS |
| ABBVIE INC. | $25.51 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391349 | CMS |
| ABBVIE INC. | $11.44 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391351 | CMS |
| ABBVIE INC. | $16.33 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391353 | CMS |
| ABBVIE INC. | $16.33 | 08/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391355 | CMS |
| ABBVIE INC. | $20.04 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391357 | CMS |
| ABBVIE INC. | $22.66 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391359 | CMS |
| ABBVIE INC. | $12.42 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391361 | CMS |
| ABBVIE INC. | $4.05 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391363 | CMS |
| ABBVIE INC. | $10.99 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103391365 | CMS |
| Galderma Laboratories, L.P. | $19.17 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145346471 | CMS |
| Galderma Laboratories, L.P. | $83.17 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145346473 | CMS |
| Novartis Pharmaceuticals Corporation | $18.03 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086654539 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.